GC
YARW

Grace Capital’s Yarrow Bioscience, Inc. Common Stock YARW Stock Holding History

Grace Capital’s Portfolio YARW Stock Details YARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-5
Closed -$28K – 258
2020
Q4 		$28K Buy
+5
New +$31.4K 0.02% 229
2020
Q3 		– Sell
-10
Closed -$62K – 247
2020
Q2 		$62K Buy
10
+7
+233% +$47.4K 0.05% 175
2020
Q1 		$32K Buy
+3
New +$47.1K 0.03% 155

Other funds holding YARW

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Grace Capital's YARW Position: Q1 2021 in Review

Grace Capital sold out of Yarrow Bioscience, Inc. Common Stock (YARW) in Q1 2021, closing a stake of 5 shares — an estimated $28K sold.

Grace Capital first reported a position in YARW in Q1 2020 and held it in 3 quarters. The position peaked at $62K in Q2 2020. 81 funds tracked by Wall St. Rank hold YARW as of Q1 2021.

  • Grace Capital reported no remaining Yarrow Bioscience, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Grace Capital sold 5 Yarrow Bioscience, Inc. Common Stock shares in Q1 2021, an estimated $28K.
  • Grace Capital first reported a position in Yarrow Bioscience, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Grace Capital's Yarrow Bioscience, Inc. Common Stock position peaked at $62K in Q2 2020.
  • 81 funds tracked by Wall St. Rank held Yarrow Bioscience, Inc. Common Stock as of Q1 2021.

Based on Grace Capital's 13F filing for Q1 2021, filed 6 May 2021.